Harrow
Sean Hardy is an experienced sales professional specializing in medical devices and pharmaceuticals, currently serving as a Field Sales Trainer at Harrow since November 2023. Previously, Sean worked as a Territory Manager at Neurolens, promoting Neurolens to Optometrists and Ophthalmologists in New Jersey and New York. Sean also held positions at Kala Pharmaceuticals, where responsibilities included selling ophthalmic products; SUN PHARMA, focusing on launching dry eye disease medication and selling glaucoma treatments; and Mylan, managing a dermatology portfolio. Sean's early career included roles in program management and laboratory assistance at Virginia Tech, complemented by a Bachelor of Science in Biology from the same institution.
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.